# Survodutide: Complete Research Profile — Dual GLP-1/Glucagon Agonist (2026)
Survodutide (development code: BI 456906) represents one of the most promising next-generation metabolic peptides in active clinical development. As a dual agonist of the glucagon-like peptide-1 (GLP-1) receptor and glucagon receptor (GCGR), survodutide offers a mechanistically distinct approach from existing GLP-1 monotherapies like semaglutide and the GIP/GLP-1 dual agonist tirzepatide. With Phase 3 trials actively enrolling for both obesity and metabolic dysfunction-associated steatohepatitis (MASH), survodutide has attracted significant research attention heading into 2026.
This profile covers survodutide's mechanism of action, published clinical trial data, safety profile, comparisons to existing agents, and its current regulatory status.
> Research Disclaimer: This article is for educational and informational purposes only. Survodutide is an investigational compound not approved for human use outside of clinical trials. All information is based on published preclinical and clinical research.
---
What Is Survodutide?
Survodutide is a synthetic peptide analog developed by Boehringer Ingelheim, structurally derived from the native glucagon sequence. A C18 fatty diacid side chain is incorporated to enable once-weekly subcutaneous dosing via lipid-protein binding and extended half-life — a strategy similar to that used in semaglutide's design.
Unlike semaglutide (GLP-1 only) or tirzepatide (GIP + GLP-1), survodutide simultaneously activates both:
- •GLP-1 receptor (GLP-1R): Reduces appetite, slows gastric emptying, and promotes insulin secretion
- •Glucagon receptor (GCGR): Increases energy expenditure, stimulates hepatic fat oxidation, and promotes lipolysis
This dual engagement is the key differentiator. By adding glucagon receptor activity to GLP-1 receptor agonism, survodutide theoretically improves fat oxidation beyond what GLP-1 agonism alone can achieve.
Research Platform: 26 listings on Peptides.SO for research-grade survodutide
---
Mechanism of Action
GLP-1 Receptor Agonism
GLP-1 receptor activation by survodutide produces effects consistent with other GLP-1 agonists:
- •Appetite suppression through central hypothalamic signaling
- •Delayed gastric emptying, reducing caloric absorption rate
- •Glucose-dependent insulin secretion, improving glycemic control
- •Reduced glucagon secretion from pancreatic alpha cells in hyperglycemic states
These effects collectively reduce caloric intake and improve post-meal glycemic profiles.
Glucagon Receptor Agonism
The addition of glucagon receptor activity creates the mechanistic novelty of survodutide:
Hepatic Effects:
- •Stimulates gluconeogenesis and glycogenolysis in the liver
- •Promotes hepatic lipid oxidation, reducing liver fat accumulation
- •Activates fatty acid beta-oxidation pathways in hepatocytes
- •Reduces de novo lipogenesis (fat synthesis from carbohydrates)
Adipose Tissue Effects:
- •Induces lipolysis — the breakdown of stored triglycerides in adipocytes
- •Increases thermogenesis via brown adipose tissue activation
- •Elevates free fatty acid mobilization for systemic energy use
Systemic Energy Expenditure:
Preclinical models demonstrated that survodutide increased resting energy expenditure to a significantly greater extent than GLP-1 receptor agonism alone. This is the key mechanistic advantage — adding glucagon receptor engagement increases calories burned at rest rather than only reducing calories consumed.
Balancing GLP-1 and Glucagon Activity
A critical design challenge with dual GLP-1/glucagon agonists is preventing the hyperglycemic effect of glucagon excess. Survodutide's GLP-1 component counterbalances glucagon's glucose-raising effects in the liver, creating a net neutral or improved glycemic profile in metabolic disease states.
---
Preclinical Research
In murine obesity models, survodutide treatment reduced body weight to a significantly greater degree than maximally effective doses of semaglutide. The superior weight loss was attributed to two mechanisms acting simultaneously:
1. Reduced energy intake (GLP-1 receptor component)
2. Increased energy expenditure (glucagon receptor component)
Liver fat reduction was pronounced in animal models, supporting the rationale for MASH trials. Hepatic steatosis markers improved substantially with survodutide treatment compared to GLP-1 monotherapy controls.
---
Phase 2 Clinical Trial Data
Phase 2 Obesity Trial (2024)
Published in: The Lancet Diabetes & Endocrinology
A randomized, double-blind, placebo-controlled, dose-finding Phase 2 trial enrolled adults with obesity (BMI ≥30 or ≥27 with comorbidities) without type 2 diabetes. Participants received once-weekly subcutaneous survodutide at doses from 0.6 mg to 4.8 mg or placebo over 46 weeks.
Weight Loss Results at Week 46:
| Dose | Mean Body Weight Change |
|---|---|
| Placebo | −2.8% |
| 0.6 mg | −6.2% |
| 2.4 mg | −12.5% |
| 3.6 mg | −13.2% |
| 4.8 mg | −14.9% |
The dose-dependent weight loss response was statistically significant across all active doses vs. placebo. The 4.8 mg dose produced nearly 15% body weight reduction — comparable to high-dose semaglutide results in the STEP trial program.
Phase 2 MASH Trial (2024)
Published in: New England Journal of Medicine
A 48-week Phase 2 trial in adults with biopsy-confirmed MASH and liver fibrosis (stages F1–F3) examined survodutide's hepatic effects.
MASH Resolution Rates (biopsy-confirmed, Week 48):
| Dose | MASH Improvement Without Fibrosis Worsening |
|---|---|
| Placebo | 14% |
| 2.4 mg | 47% |
| 4.8 mg | 62% |
| 6.0 mg | 43% |
Liver Fat Reduction (≥30% reduction from baseline):
- •Placebo: 14%
- •Survodutide 2.4 mg: 63%
- •Survodutide 4.8 mg: 67%
- •Survodutide 6.0 mg: 57%
Fibrosis Improvement (≥1 stage improvement):
- •Placebo: 22%
- •Survodutide 2.4 mg: 34%
- •Survodutide 4.8 mg: 36%
- •Survodutide 6.0 mg: 34%
Notably, up to 83% of participants in active dose groups achieved clinically meaningful improvement in MASH without fibrosis worsening — a landmark result that secured FDA Breakthrough Therapy Designation for survodutide in MASH.
---
FDA Breakthrough Therapy Designation
Based on Phase 2 MASH data, the FDA granted Breakthrough Therapy Designation to survodutide for the treatment of non-cirrhotic MASH with moderate-to-advanced fibrosis (stages F2–F3). This designation signals that the FDA views survodutide's preliminary evidence as showing substantial improvement over existing therapies and facilitates expedited development and review.
---
Phase 3 Trials (Active, 2025–2026)
SYNCHRONIZE™-1 (Obesity Without T2D)
- •Design: Randomized, double-blind, placebo-controlled, 76-week study
- •Population: Adults with BMI ≥30 or ≥27 with ≥1 obesity complication, without type 2 diabetes
- •Doses: Survodutide 3.6 mg or 6.0 mg once weekly vs. placebo
- •Primary Endpoint: Percentage body weight change at week 76
SYNCHRONIZE™-2 (Obesity With T2D)
Parallel Phase 3 for individuals with obesity and type 2 diabetes. Baseline characteristics were published in Diabetes, Obesity and Metabolism in 2026.
SYNCHRONIZE-CVOT (Cardiovascular Outcomes)
- •Design: Phase 3 cardiovascular safety study
- •Population: Adults with BMI ≥27 and established cardiovascular disease or chronic kidney disease
- •Target Enrollment: 4,935 participants
- •Primary Endpoint: Time to first occurrence of 5-point MACE (major adverse cardiovascular events)
LIVERAGE Trials (MASH)
- •LIVERAGE: 52-week MASH/fibrosis improvement endpoint plus ~7-year liver disease outcome study in F2–F3 fibrosis
- •LIVERAGE-Cirrhosis: ~4.5-year liver disease outcome study in compensated cirrhosis (F4)
---
Comparison to Other Metabolic Agents
| Feature | Survodutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Receptor Targets | GLP-1 + Glucagon | GIP + GLP-1 | GLP-1 only |
| Regulatory Status | Phase 3 | Approved | Approved |
| Dosing Frequency | Once weekly | Once weekly | Once weekly |
| Route | Subcutaneous | Subcutaneous | Subcutaneous |
| Phase 2 Max Weight Loss | ~14.9% | ~20.9% | ~14.9% |
| MASH Data | Strong Phase 2 | Limited | Limited |
| Energy Expenditure Effect | Direct (GCGR) | Modest | Minimal |
Key Distinguishing Factor: Survodutide's glucagon receptor component increases energy expenditure more directly than tirzepatide's GIP receptor component. For MASH specifically, hepatic glucagon receptor activity provides a mechanistic rationale for superior liver fat reduction. Phase 3 results will determine whether these mechanistic advantages translate to differentiated clinical outcomes vs. approved agents.
---
Safety Profile
Overall Adverse Event Rates (Phase 2 Obesity Trial):
- •Survodutide recipients: 91% experienced at least one adverse event
- •Placebo recipients: 75%
Gastrointestinal Adverse Events (most common class):
- •Survodutide group: ~75% (nausea, vomiting, diarrhea, decreased appetite)
- •Placebo group: ~42%
The GI profile is consistent with other GLP-1 receptor agonists. Most events were mild-to-moderate, occurred during dose escalation, and resolved with continued use or dose reduction.
Research Monitoring Parameters for Glucagon Receptor Agonism:
- •Glycemic status (potential glucagon-mediated glucose elevation, counterbalanced by GLP-1)
- •Heart rate (mild increases reported with glucagon receptor activation)
- •Bone metabolism (long-term glucagon effects on bone are an active research area)
Serious Adverse Events: Rates were low in Phase 2 studies and consistent with the metabolic disease population being studied. No unexpected safety signals were reported.
---
Research Context and Platform Availability
Survodutide sits at the intersection of several high-growth research areas:
Obesity Pharmacotherapy: The obesity drug market is expanding rapidly following the success of semaglutide and tirzepatide. Survodutide's differentiated mechanism positions it as a potential next-generation obesity treatment.
MASH Treatment Pipeline: MASH (formerly NASH) represents a significant unmet medical need. Survodutide's FDA Breakthrough Therapy Designation and strong Phase 2 liver data make it one of the most closely watched MASH pipeline agents.
Dual Receptor Agonist Research: The GLP-1/glucagon dual agonist class — which also includes mazdutide — is generating substantial research interest as a mechanistically superior alternative to GLP-1 monotherapy for specific indications.
For research procurement, Peptides.SO lists 26 vendors offering research-grade survodutide. Use our peptide comparison tool to evaluate sourcing options and peptide calculator for research dosing frameworks.
---
Frequently Asked Questions
Q: What is survodutide used for in research?
Survodutide (BI 456906) is studied for obesity, type 2 diabetes, and MASH (metabolic dysfunction-associated steatohepatitis). Research focuses on its dual GLP-1/glucagon receptor mechanism, which drives both appetite reduction and increased energy expenditure.
Q: How does survodutide differ from semaglutide?
Semaglutide targets only GLP-1 receptors. Survodutide additionally targets glucagon receptors, increasing energy expenditure and hepatic fat oxidation. Both achieved similar maximum weight loss in Phase 2 (~14.9%), but survodutide shows significantly stronger liver-specific effects, including 62–83% MASH improvement rates vs. 14% for placebo.
Q: How does survodutide differ from tirzepatide?
Tirzepatide combines GIP + GLP-1 receptor agonism; survodutide combines glucagon + GLP-1 receptor agonism. GIP agonism primarily improves insulin secretion and may reduce GI side effects. Glucagon agonism primarily increases energy expenditure and liver fat oxidation. These mechanisms produce distinct efficacy profiles, particularly for liver-focused endpoints.
Q: Is survodutide approved?
No. Survodutide is investigational and not approved for human use outside of clinical trials as of 2026. Phase 3 trials are actively enrolling.
Q: What is the SYNCHRONIZE trial program?
SYNCHRONIZE is Boehringer Ingelheim's Phase 3 clinical trial program for survodutide in obesity. It includes SYNCHRONIZE-1 (obesity without T2D), SYNCHRONIZE-2 (obesity with T2D), and SYNCHRONIZE-CVOT (cardiovascular outcomes).
Q: What is the LIVERAGE trial?
LIVERAGE is Boehringer Ingelheim's Phase 3 MASH trial program for survodutide. It evaluates fibrosis improvement at 52 weeks and long-term liver disease outcomes over approximately 7 years.
Q: What dose of survodutide is used in Phase 3?
Phase 3 obesity trials use 3.6 mg and 6.0 mg doses, administered once weekly subcutaneously. MASH trials are evaluating similar dose ranges.
---
Key Research References
1. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: Phase 2 trial. The Lancet Diabetes & Endocrinology, 2024.
2. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. New England Journal of Medicine, 2024.
3. SYNCHRONIZE™-2 Phase 3 baseline characteristics. Diabetes, Obesity and Metabolism, 2026.
4. SYNCHRONIZE™-1 baseline characteristics. PubMed, 2025.
5. FDA Breakthrough Therapy designation and LIVERAGE Phase III trials. GlobeNewswire, 2024.
6. Boehringer Ingelheim Survodutide MASH Phase 2 results. Boehringer Ingelheim, 2024.
---
Further Reading:
- •Mazdutide: Complete Research Profile — GLP-1/Glucagon Dual Agonist (2026)
- •Cagrilintide: Complete Research Profile — Long-Acting Amylin Analog, CagriSema Trials & GLP-1 Comparison (2026)
- •GHK-Cu Peptide Research Guide: Anti-Aging Science, Applications, and Best Sources (2026)
- •PYY (Peptide YY): Complete Research Profile — The Gut Satiety Hormone in Appetite Regulation and Obesity Research (2026)
- •Peptide Stack Builder
- •Dosage Chart
---
This article is for educational and research purposes only. Survodutide is an investigational compound not approved for human use. This content does not constitute medical advice.